Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seviteronel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 known ✓ | P05093 | 13/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seviteronel SCHEMBL29364397 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL30596789 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL4561168 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL20459170 | 1.00 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020315 | 0.89 | CYP3A4 (0.68) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020196 | 0.88 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL8745699 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4560966 | 0.82 | CYP3A4 (0.47) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL29892874 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL29892604 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387394-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | GARVAN INSTITUTE OF MEDICAL RES (AU) | 2022-12-08 | — | — | US | disclosed |
| WO-2021077174-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387394-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | AR, GNRHR, KLK3 | CYP17A1 17/4885CYP3A4 3376/4885CYP2C9 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.